The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 08, 2016

Filed:

Dec. 09, 2010
Applicants:

Stephen Robert Tennison, Surrey, GB;

Oleksandr Prokopovyeh Kozynchenko, Hampshire, GB;

Anthony Paul Rawlinson, Middlesex, GB;

Gary James Phillips, Sussex, GB;

Carol Angela Howell, West Sussex, GB;

Susan Rachel Sandeman, East Sussex, GB;

Sergey Victorovich Mikhalovsky, East Sussex, GB;

Inventors:

Stephen Robert Tennison, Surrey, GB;

Oleksandr Prokopovyeh Kozynchenko, Hampshire, GB;

Anthony Paul Rawlinson, Middlesex, GB;

Gary James Phillips, Sussex, GB;

Carol Angela Howell, West Sussex, GB;

Susan Rachel Sandeman, East Sussex, GB;

Sergey Victorovich Mikhalovsky, East Sussex, GB;

Assignee:

IMMUNTRIX THERAPEUTICS, INC., Rapid City, SD (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61M 37/00 (2006.01); A61M 1/34 (2006.01); A61M 1/36 (2006.01);
U.S. Cl.
CPC ...
A61M 1/34 (2013.01); A61M 1/3486 (2013.01); A61M 1/362 (2014.02); A61M 1/3496 (2013.01); A61M 2202/0057 (2013.01); A61M 2202/0407 (2013.01); A61M 2202/07 (2013.01); A61M 2202/08 (2013.01); A61M 2202/203 (2013.01);
Abstract

Whole blood is treated extracorporeally to remove substances contrary to health using mesoporous/microporous or macroporopus/microporous carbon in the form of beads or a channel monolith. The carbon may be the result of carbonizing a mesoporous or macroporous phenolic resin. Substances contrary to health include externally introduced toxins such as bacterially derived staphylococcus enterotoxins A, B, TSST-1 or autologous, biologically active molecules with harmful, systemic effects when their activity is excessive or unregulated. Examples include the removal of inappropriate amounts of pro- or anti-inflammatory molecules and toxic mediators of systemic inflammatory response syndrome related to sepsis, cardio-pulmonary by-pass surgery, ischaemic reperfusion injury; the removal of larger molecular weight and protein bound uremic toxins related to kidney and hepatic toxins related to liver failure and the removal of toxins relevant to biological and chemical warfare.


Find Patent Forward Citations

Loading…